Taha Tavaci

Taha Tavaci

Auto-generated profile, based on publicly available information

Taha Tavaci

Department of Internal Medical Sciences, Division of Medical Pharmacology, Faculty of Medicine, Sakarya University, 54050, Sakarya, Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2025 in Inflammopharmacology
Verified
Journal Article
Open access
TTTaha Tavaci
Taha Tavaci
ZHZekai Halici
Zekai Halici
ECElif Cadirci
Elif Cadirci
MOMustafa Ozkaraca
Mustafa Ozkaraca
KKKamber Kasali
Kamber Kasali
Background: Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. Due to the high mortality rates and treatment costs associated with sepsis, research is focusing on innovative treatment strategies to replace one dimensional approaches. Recent studies are being conducted on the use of immunotherapeutics in sepsis and the impact of treatment timing. This study aimed to elucidate the significance of treatment timing in sepsis immunotherapy with Tocilizumab (TCZ) and the implications of differences in treatment timing. Methods: LPS-induced sepsis model was established in rats to assess the changes in interleukin-6 (IL-6) over a 24-h sepsis period and its correlation with lung and kidney injury. The impact of TCZ treatments at various time points was evaluated by molecular and histopathological methods. The effect of TCZ treatment timing on survival was analyzed using Kaplan–Meier survival analysis. Results: IL-6 reached peak concentrations in the early stages of sepsis, whereas lung damage peaked subsequent to the IL-6 peak, and kidney damage manifested considerably later. The early treatment group, receiving intervention one hour post-sepsis induction, exhibited the most favorable molecular and histopathological outcomes. Conversely, the group receiving the latest treatment, at sixteen hours post-sepsis induction, demonstrated the poorest results. Survival analysis indicated that the group treated at the tenth hour exhibited the highest survival rate. Conclusion: Variations in the timing of sepsis treatment with TCZ yield significantly different molecular outcomes, histopathological results, and survival rates. A thorough investigation of the timing of immunotherapeutic applications in sepsis treatment will enhance the efficiency of sepsis treatments.

1 January 2022 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
TTTaha Tavaci
Taha Tavaci
NANurullah Akgun
Nurullah Akgun
Sepsis is a syndrome that includes physiological, pathological, and biochemical abnormalities resulting from the host immune response to infection. Despite the improved treatment modalities in recent years, the incidence and mortality of sepsis are still increasing. Sepsis immunopathology is increasingly attracting the attention of researchers. The successes experienced with immunotherapeutics in the treatment of cancer and coronavirus disease 2019, which are diseases with similar pathophysiological features and common immune defects with sepsis, have given rise to the hope that similar successes can be achieved in the treatment of sepsis. In this review, future perspectives on the immunopathology of sepsis and immunotherapeutics are presented to improve the current understanding of the disease. Cite this article as: Tavaci T, Akgun N. Sepsis: Immunopathology, immunotherapies, and future perspectives. Eurasian J Med., 2022;54(Suppl. 1):S127-S132

7 February 2025 in The Protein Journal
Verified
Journal Article
Closed access
PDF file
MÇMine Gürsaç Çelik
Mine Gürsaç Çelik
MKMehmet Koca
Mehmet Koca
ZHzekai halici
zekai halici
TTTaha Tavaci
Taha Tavaci
HHHamza Halici
Hamza Halici
ZBZafer Bayraktutan
Zafer Bayraktutan

30 March 2023 in Thoracic Research and Practice
Verified
Journal Article
Open access
AAAlperen Aksakal
Alperen Aksakal
AKAdil Furkan Kılıç
Adil Furkan Kılıç
UTUgurcan Tanulku
Ugurcan Tanulku
TTTaha Tavaci
Taha Tavaci
NBNurcan Kılıç Baygutalp
Nurcan Kılıç Baygutalp
Health,interleukin-28,marker,Sars-Cov-2

15 September 2023 in Namık Kemal Tıp Dergisi
Verified
Journal Article
Open access
TYTuğba Nurcan YUKSEL
Tuğba Nurcan YUKSEL
ZHzekai halici
zekai halici
CKCihangir Kaya
Cihangir Kaya
ABAyşe BOZKURT
Ayşe BOZKURT
TTTaha Tavaci
Taha Tavaci
BÖBengül Özdemi̇r
Bengül Özdemi̇r

2 December 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ZKZerrin Kutlu
Zerrin Kutlu
ZHzekai halici
zekai halici
TTTaha Tavaci
Taha Tavaci
SKSaliha Sena Karcioğlu
Saliha Sena Karcioğlu
SYSerkan YILDIRIM
Serkan YILDIRIM
ZCZeynep Celik
Zeynep Celik